The newly approved product is a generic therapeutic equivalent version of GlaxoSmithKline s Imitrex Nasal Spray. The company has received final approval for its abbreviated new drug application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (USFDA), Cipla said in a regulatory filing. Quoting IQVIA (IMS Health) data, Cipla said Imitrex Nasal Spray 20mg and its generic equivalents had US sales of approximately USD 53.3 million for the 12-month period ending December 2020. Shares of Cipla were trading 0.88 per cent higher at Rs 796.45 apiece on BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Cipla has received final approval for its
Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the
United States Food and Drug Administration (USFDA).
Cipla s Sumatriptan Nasal Spray USP, 20 mg is an AB-rated generic therapeutic
equivalent version of GlaxoSmithKline s Imitrex Nasal Spray.
Imitrex Nasal Spray is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for
acute treatment of migraine with or without aura in adults.
According to IQVIA (IMS Health), Imitrex Nasal Spray 20mg and its generic equivalents
had US sales of approximately $53.3M for the 12-month period ending December 2020.
Powered by Capital Market - Live News
Mumbai (Maharashtra) [India], March 2 (ANI/PRNewswire): Cipla Limited today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (U.S. FDA).
Cipla receives final approval for generic version of GlaxoSmithKline s IMITREX (Sumatriptan Nasal Spray, 20 mg) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.